Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Goodman

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Neurology|August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman, T R Brown, J A Cohen, et al.
Neurology|December 31, 1997
The measurement of ambulatory impairment in multiple sclerosisS R Schwid, A D Goodman, D H Mattson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Neurology|March 4, 2009
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyA D Goodman, H Rossman, A Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 29, 2010
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateC Ford, A D Goodman, K Johnson, et al.
Neurology|January 3, 2001
Are quantitative functional measures more sensitive to worsening MS than traditional measures?S R Schwid, A D Goodman, B R Apatoff, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
Journal of Neurovirology|August 27, 1999
Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathyD J Mock, J M Powers, A D Goodman, et al.
Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.
Archives of Neurology|June 19, 2001
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen, G R Cutter, J S Fischer, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Neurology|August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman, T R Brown, J A Cohen, et al.
Neurology|December 31, 1997
The measurement of ambulatory impairment in multiple sclerosisS R Schwid, A D Goodman, D H Mattson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Neurology|March 4, 2009
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyA D Goodman, H Rossman, A Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 29, 2010
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateC Ford, A D Goodman, K Johnson, et al.
Neurology|January 3, 2001
Are quantitative functional measures more sensitive to worsening MS than traditional measures?S R Schwid, A D Goodman, B R Apatoff, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
Journal of Neurovirology|August 27, 1999
Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathyD J Mock, J M Powers, A D Goodman, et al.
Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.
Archives of Neurology|June 19, 2001
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen, G R Cutter, J S Fischer, et al.
Pageof 7